CR20220247A - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents

Uso de reboxetina para tratar los trastornos del sistema nervioso

Info

Publication number
CR20220247A
CR20220247A CR20220247A CR20220247A CR20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A
Authority
CR
Costa Rica
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
esreboxetine
Prior art date
Application number
CR20220247A
Other languages
English (en)
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of CR20220247A publication Critical patent/CR20220247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CR20220247A 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso CR20220247A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
CR20220247A true CR20220247A (es) 2022-08-18

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220247A CR20220247A (es) 2019-12-03 2020-11-30 Uso de reboxetina para tratar los trastornos del sistema nervioso

Country Status (12)

Country Link
EP (1) EP4069244A4 (de)
JP (1) JP2023504685A (de)
KR (1) KR20220108122A (de)
CN (1) CN114746097A (de)
AU (1) AU2020395082A1 (de)
BR (1) BR112022010677A2 (de)
CA (1) CA3163505A1 (de)
CO (1) CO2022007507A2 (de)
CR (1) CR20220247A (de)
IL (1) IL293536A (de)
MX (1) MX2022006630A (de)
PE (1) PE20230181A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197985B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
SI2968208T1 (sl) * 2013-03-13 2023-02-28 Jazz Pharmaceuticals Ireland Limited, Zdravljenje katapleksije

Also Published As

Publication number Publication date
MX2022006630A (es) 2022-06-24
IL293536A (en) 2022-08-01
AU2020395082A1 (en) 2022-06-09
EP4069244A1 (de) 2022-10-12
JP2023504685A (ja) 2023-02-06
BR112022010677A2 (pt) 2022-08-16
EP4069244A4 (de) 2023-12-20
CN114746097A (zh) 2022-07-12
PE20230181A1 (es) 2023-02-01
CA3163505A1 (en) 2021-06-10
CO2022007507A2 (es) 2022-06-21
KR20220108122A (ko) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2019012884A (es) Terapia de combinacion.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2021002322A (es) Nuevos metodos.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MY187167A (en) Medical treatments based on anamorelin
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
EA202193276A1 (ru) Способы лечения холангиокарциномы
CR20220247A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
MX2022012001A (es) Tratamiento preventivo de la migra?a.
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal